News
Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
Regulatory News:
Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.
Vifor Pharma Group Reports Continued Growth in H1 2020
Regulatory News:
Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect
Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter
Regulatory News:
Die Vifor Pharma Gruppe ist trotz der Herausforderungen, die Patienten auch während der COVID-19-Pandemie zu erreichen, im 1. Halbjahr 2020 weiter gewachsen. Die Finanzprognose
VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005052/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
92. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der 92. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt.
Aufgrund der aktuellen Situation und im
92nd Vifor Pharma Group Annual General Meeting
Regulatory News:
At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
In view of the current situation
Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients
Regulatory News:
Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes
BB Biotech: So geht Rendite mit COVID-19-Aktien!
Interessante Einblicke in den Geschäftsverlauf im Auftaktquartal liefert heute BB Biotech (WKN: A0NFN3). Die mussten zwar Rückschläge einstecken, glänzten aber auch durch Überraschungen – die mit
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005949/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Update on 92nd Vifor Pharma Ltd. Annual General Meeting
Regulatory News:
Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2
Update zur 92. Generalversammlung der Vifor Pharma AG
Regulatory News:
Vifor Pharma hat bestätigt, dass die Generalversammlung des Unternehmens wie geplant am 14. Mai 2020 abgehalten wird. Aufgrund der aktuellen Situation und im Einklang mit Art. 6a
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Regulatory News:
Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The
Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose
Regulatory News:
Die Vifor Pharma Gruppe erzielte 2019 ein starkes finanzielles und operatives Ergebnis dank Fokus auf die drei strategischen Wachstumstreiber und gezielten Investitionen in die
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings
Regulatory News:
Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This investment
Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio
Vifor Pharma today announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the second largest
BB Biotech: Ausschau nach „lukrativen Anlagechancen“
BB Biotech (WKN: A0NFN3) publiziert heute seine ersten Zahlen für das abgelaufene Geschäftsjahr. Aktionäre können sich freuen, denn als Dividende will die Schweizer Gesellschaft 3,40 CHF pro Aktie
Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005728/en/
Iron Deficiency Day is an international event which
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005734/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma Appoints Lee Heeson as President International and Member of the Executive Committee
Regulatory News:
Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020.
Lee Heeson joins Vifor
Vifor Pharma and Evotec form joint venture for early development in nephrology
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005841/en/
Vifor Pharma and Evotec SE today announced the
Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen
Regulatory News:
Vifor Pharma today announced a commercial partnership with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to jointly
BB Biotech: Kurzfristige, temporäre Schwäche kaufenswert
Der Schweizer Biotechnologie-Investor BB Biotech (WKN: A0NFN3) hat heute seine aktuellen Quartalszahlen vorgelegt. Demnach wurde in den ersten neun Monaten des laufenden Geschäftsjahres 2019 ein
Santhera: Vamorolone droht zu scheitern – an der Konkurrenz!
Große Hoffnung setzen Anleger von Santhera (WKN: A0LCUK) in den einlizenzierten DMD-Medikamentenkandidaten Vamorolone und übersehen dabei offensichtlich völlig: Das Steroid wird in Zukunft
Can Marijuana Cure Alzheimer's Disease?
Why Advanced Accelerator Applications SA Acquired a Higher Price Today